Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing

American Journal of Hematology

Volumn 91, Issue 5, 2016, Pages 492-498

  Patnaik, Mrinal M ^a   Lasho, Terra L ^a   Finke, Christy M ^a   Hanson, Curtis A ^a   King, Rebecca L ^a   Ketterling, Rhett P ^a   Gangat, Naseema ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; AZACITIDINE; CD135 ANTIGEN; DECITABINE; DNA METHYLTRANSFERASE 3A; HYDROXYUREA; IMETELSTAT; JANUS KINASE 2; LENALIDOMIDE; SMALL NUCLEAR RNA; ASXL1 PROTEIN, HUMAN; CARRIER PROTEIN; HEMOGLOBIN; JAK2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; REPRESSOR PROTEIN; SETBP1 PROTEIN, HUMAN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; STOP CODON;

ADULT; AGED; ARTICLE; ASXL1 GENE; BONE MARROW BIOPSY; CARDIOVASCULAR RISK; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; FEMALE; GENE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; NEUTROPHIL COUNT; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH RING SIDEROBLASTS AND THROMBOCYTOSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SETBP1 GENE; SF3B1 GENE; SRSF2 GENE; SURVIVAL PREDICTION; TET2 GENE; THROMBOCYTOSIS; TRISOMY 8; VERY ELDERLY; BONE MARROW; CHEMISTRY; COMPARATIVE STUDY; COMPLICATION; DISEASE COURSE; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; FRAMESHIFT MUTATION; GENETICS; KAPLAN MEIER METHOD; KARYOTYPING; MORTALITY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REFRACTORY ANEMIA WITH EXCESS BLASTS; SIDEROBLASTIC ANEMIA; STOP CODON;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANEMIA, SIDEROBLASTIC; BONE MARROW; CARRIER PROTEINS; CHROMOSOME ABERRATIONS; CODON, NONSENSE; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; FRAMESHIFT MUTATION; HEMOGLOBINS; HUMANS; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; KARYOTYPING; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRESSOR PROTEINS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; SEQUENCE ANALYSIS, DNA; THROMBOCYTOSIS;

EID: 84962724166     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24332     Document Type: Article

References (25)

1. Swerdlow S, Camp E, Harris NL, et al., editor. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.
2. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol 2015; 90:549-559.
3. Jeromin S, Haferlach T, Weissmann S, et al. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica 2015; 100:e125-e127.
4. Broseus J, Florensa L, Zipperer E, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012; 97:1036-1041.
5. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119:569-572.
6. Broseus J, Lippert E, Harutyunyan AS, et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2014; 28:1374-1376.
7. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369:2379-2390.
8. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369:2391-2405.
9. Broseus J, Alpermann T, Wulfert M, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27:1826-1831.
10. Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013; 27:1504-1510.
11. Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients. Leukemia 2014; 28:2206-2212.
12. Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373:908-919.
13. Patnaik MM, Lasho TL, Finke CM, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013; 88:201-206.
14. Patnaik MM, Hanson CA, Sulai NH, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood 2012; 119:5674-5677.
15. Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013; 27:1870-1873.
16. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368:1781-1790.
17. Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013; 45:942-946.
18. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45:18-24.
19. Patnaik MM, Lasho TL, Vijayvargiya P, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J 2016; 6:e385
20. Laborde RR, Patnaik MM, Lasho TL, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: Independent prognostic impact in CMML. Leukemia 2013; 27:2100-2102.
21. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25:1200-1202.
22. Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012; 22:180-193.
23. Balasubramani A, Larjo A, Bassein JA, et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun 2015; 6:7307
24. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436.
25. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013;122:3616-3627. quiz 3699.